|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.50 HKD | -0.50% |
|
-1.97% | +4.26% |
| 02-05 | Novo reports first Ozempic sales drop in greater China region | RE |
| 02-04 | Innovent Biologics, Inc. Reports Product Revenue for the Fourth Quarter and Full Year of 2025 | CI |
| Capitalization | 122B 138B 17.65B 14.94B 13.69B 12.97B 24.08B 1,599B 25.18B 159B 62.99B 770B 66.19B 64.82B 2,771B | P/E ratio 2025 * |
73.2x | P/E ratio 2026 * | 35.4x |
|---|---|---|---|---|---|
| Enterprise value | 113B 127B 16.23B 13.74B 12.59B 11.93B 22.15B 1,471B 23.15B 146B 57.94B 708B 60.87B 59.62B 2,548B | EV / Sales 2025 * |
8.58x | EV / Sales 2026 * | 6.25x |
| Free-Float |
93.21% | Yield 2025 * |
-
| Yield 2026 * | 0.08% |
Last Transcript: Innovent Biologics, Inc.
| 1 day | -0.50% | ||
| 1 week | -1.97% | ||
| Current month | -1.97% | ||
| 1 month | -5.92% | ||
| 3 months | -9.97% | ||
| 6 months | -18.92% | ||
| Current year | +4.26% |
| 1 week | 76.75 |  | 81.85 |
| 1 month | 76.75 | | 92.75 |
| Current year | 76.75 | | 92.75 |
| 1 year | 34.65 | | 109.1 |
| 3 years | 27.3 | | 109.1 |
| 5 years | 18.06 | | 109.1 |
| 10 years | 14 | | 109.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 62 | 28/04/2011 |
Fei You
DFI | Director of Finance/CFO | 47 | 05/02/2024 |
Ghang Shou Gao
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CHM | Chairman | 62 | 28/04/2011 |
Charles Cooney
BRD | Director/Board Member | 81 | 18/10/2015 |
Hao Xi Ede
BRD | Director/Board Member | 67 | 04/06/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.50% | -1.97% | +122.07% | +85.96% | 17.65B | |
| +2.46% | +5.94% | +8.79% | +0.60% | 80.61B | |
| -0.41% | -0.51% | -33.85% | -42.13% | 61B | |
| -2.31% | +2.58% | +40.75% | +243.47% | 58.81B | |
| -1.88% | +66.80% | +66.80% | +66.80% | 52.77B | |
| +8.53% | +11.84% | +41.31% | -30.21% | 29.52B | |
| +5.48% | +8.31% | +44.62% | +28.49% | 21.28B | |
| +0.34% | -6.94% | +22.02% | -75.91% | 16.02B | |
| +2.27% | +17.45% | +19.72% | +67.71% | 15.17B | |
| -0.04% | -.--% | +3.74% | +177.50% | 14.02B | |
| Average | +1.39% | +2.75% | +33.59% | +52.23% | 36.69B | |
| Weighted average by Cap. | +0.92% | +2.65% | +26.15% | +51.39% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 13.13B 14.79B 1.89B 1.6B 1.47B 1.39B 2.58B 171B 2.7B 17.07B 6.76B 82.55B 7.1B 6.95B 297B | 17.6B 19.82B 2.54B 2.15B 1.97B 1.86B 3.46B 230B 3.62B 22.87B 9.05B 111B 9.51B 9.32B 398B |
| Net income | 1.64B 1.85B 237M 201M 184M 174M 323M 21.48B 338M 2.14B 846M 10.34B 889M 871M 37.22B | 3.41B 3.84B 492M 416M 382M 361M 671M 44.56B 702M 4.43B 1.76B 21.45B 1.84B 1.81B 77.22B |
| Net Debt | -9.83B -11.07B -1.42B -1.2B -1.1B -1.04B -1.93B -128B -2.02B -12.77B -5.06B -61.78B -5.31B -5.2B -222B | -12.44B -14.01B -1.79B -1.52B -1.39B -1.32B -2.45B -162B -2.56B -16.16B -6.4B -78.19B -6.72B -6.59B -281B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/02/26 | 79.50 $ | -0.50% | 8,294,071 |
| 05/02/26 | 79.90 $ | -0.93% | 15,014,520 |
| 04/02/26 | 80.65 $ | +2.35% | 9,258,513 |
| 03/02/26 | 78.80 $ | +0.13% | 6,865,767 |
| 02/02/26 | 78.70 $ | -2.96% | 8,446,227 |
Delayed Quote Hong Kong S.E., February 06, 2026 at 12:08 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1801 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition